Barclays
APVO icon

Barclays’s Aptevo Therapeutics APVO Stock Holding History

Barclays’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-31
Closed -$138 – 5389
2026
Q2 		$138 Buy
+31
New +$149 ﹤0.01% 5159
2022
Q3 		– Hold
0
– -$283K – 4772
2022
Q2 		– Hold
0
– – – 3231
2022
Q1 		– Hold
0
– – – 3052
2018
Q4 		– Hold
0
– -$105K – 6905
2018
Q3 		– Hold
0
– – – 5493
2018
Q2 		– Hold
0
– – – 5220
2018
Q1 		– Hold
0
– – – 5662
2017
Q4 		– Hold
0
– – – 5347
2017
Q3 		– Hold
0
– – – 6825
2017
Q2 		– Hold
0
– – – 6616
2017
Q1 		– Hold
0
– – – 5719
2016
Q4 		– Hold
0
– – – 6587
2016
Q3 		– Hold
0
– – – 6585

Other funds holding APVO

SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Barclays's APVO Position: Q3 2026 in Review

Barclays sold out of Aptevo Therapeutics (APVO) in Q3 2026, closing a stake of 31 shares — an estimated $138 sold.

Barclays first reported a position in APVO in Q2 2026 and held it in 1 quarter. The position peaked at $138 in Q2 2026. 2 funds tracked by Wall St. Rank hold APVO as of Q3 2026.

  • Barclays reported no remaining Aptevo Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 31 Aptevo Therapeutics shares in Q3 2026, an estimated $138.
  • Barclays first reported a position in Aptevo Therapeutics in Q2 2026 and held it in 1 quarter.
  • Barclays's Aptevo Therapeutics position peaked at $138 in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.